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Cholera is an acute diarrheal disease that is caused by the gram-negative bacterium Vibrio cholerae. The low
efficacy of currently available killed-whole-cell vaccines and the reactinogenicity coupled with potential reversion of live vaccines have thus far precluded widespread vaccination for the control of cholera. Recent studies
on the molecular nature of the virulence components that contribute to V. cholerae pathogenesis have provided
insights into possible approaches for the development of a defined subunit cholera vaccine. Genetic analysis
has demonstrated that the toxin-coregulated pilus (TCP) is the major factor that contributes to colonization
of the human intestine by V. cholerae. In addition, polyclonal and several monoclonal antibodies directed
against TCP have been shown to provide passive immunity to disease in the infant mouse cholera model. In the
present study, synthetic peptides corresponding to portions of the C-terminal disulfide region of TcpA pilin
were formulated with polymer adjuvants currently in clinical trials and used to actively immunize adult female
CD-1 mice. The experimental vaccine formulations elicited high levels of antigen-specific immunoglobulin G
(IgG), including a broad spectrum of subclasses (IgG1, IgG2a, IgG2b, and IgG3), and lower levels of IgA.
Infant mice born to the immunized mothers showed 100% protection against a 50% lethal dose (1 LD50)
challenge and 50% protection against a 10-LD50 challenge with virulent strain O395. These results indicate
that specific regions of TcpA, including those delineated by the peptides used in this study, have the potential
to be incorporated into an effective defined subunit vaccine for cholera.
Infection by Vibrio cholerae remains a major cause of morbidity and mortality throughout the world (2). Adequate supplies of uncontaminated food and water coupled with proper
sanitary measures, if supported by the appropriate infrastructure, would control cholera, but, unfortunately, this is still not
feasible for many affected countries. An alternate means to
control cholera is an effective economical cholera vaccine that
would mitigate the spread of cholera and stabilize areas of
endemicity.
Currently, the following two types of cholera vaccines are
approved and in general use for humans: (i) a killed-whole-cell
formulation representing both biotypes and serotypes representative of serogroup O1 (35) that is combined with the purified cholera toxin (CT-B) subunit and (ii) a genetically engineered, live-attenuated V. cholerae vaccine (e.g., CVD 103HgR, O1, classical biotype, Inaba serotype) (17). Multiple
doses of the killed-whole-cell vaccine afforded 50% protection
in field trials. The most important target population for a
cholera vaccine, young children, was even less well protected
by this vaccine (less than 25%) (6). A single dose of the liveattenuated vaccine used in clinical trials of North American
adults provided ⬎90% protection against the virulent homologous strain and 65 to 80% protection against virulent El Tor
biotype, Inaba serotype strains (18, 37, 38). Administration of
the CVD 103-HgR vaccine in a large-scale field trial in an area
of endemicity of Indonesia did not show any correlation between vaccination and increased protection (12). Another new
oral vaccine strain CVD 111, which is a live-attenuated El Tor

biotype, Ogawa serotype strain, provided 80% protection in
adult volunteers (36). This vaccine is being evaluated together
with CVD 103-HgR to determine if the combination can provide further protection against both biotypes in a single dose
(40).
Despite the potential of live vaccine strains, two problems
are related to their use. First, the live-attenuated strains cause
side effects such as mild diarrhea, abdominal cramps, and low
fever. Second, because these live strains are attenuated by
deleting the ctx genes that are carried on a bacteriophage,
there is concern that infection of vaccine strains by ctx-carrying
phage may lead to reversion to virulence if these vaccines are
used in regions where cholera is endemic (15).
An alternative approach to cholera vaccine design is the
development of a subunit vaccine. Research during the last
decade has provided new insights into the molecular mechanisms of V. cholerae pathogenesis. Prominent among these is
the identification and characterization of the major colonization factor, toxin-coregulated pilus (TCP) (13, 16, 28, 31, 33,
34, 39, 41). TCP and its antigens are obvious targets for testing
for inclusion in a subunit cholera vaccine. Of note, there is very
little TCP detectable in the commercially available killedwhole-cell cholera vaccines (31), perhaps due to certain culture
conditions that need to be optimized for TCP expression.
TCP is composed of a homopolymer of TcpA pilin, which is
a 20.5-kDa pilin subunit (41). Rabbit polyclonal antibodies
directed against TCP provide 100% protection against a challenge with 100 times the 50% lethal dose (100 LD50) in the
infant mouse cholera model (31). Various levels of protection
in the infant mouse cholera model were achieved by passive
administration of monoclonal antibodies (MAbs) raised
against TCP. All the MAbs recognized TcpA, but the most
protective MAbs mapped to the C-terminal region of the pilin
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(32, 33). Synthetic peptides TcpA4, TcpA5, and TcpA6 represent contiguous overlapping peptides corresponding to the carboxyl disulfide bond region of the TcpA pilin. Peptides 5 and 6
were recognized by protective MAbs. In other studies, rabbit
antibodies raised against TcpA peptides 4 and 6 were found to
be the most protective while antibodies to peptide 5 afforded
some protection (34).
One of the problems of utilizing a peptide-based antigen is
that, because of their small size, peptides are not likely to elicit
a robust stimulation of the immune system. The inclusion of
the appropriate adjuvant in vaccine formulations can overcome this problem (9). Polydi(carboxylatophenoxy) phosphazene (PCPP) (Avant Immunotherapeutics, Inc., Needham,
Mass.) is a water-based ionically cross-linkable polymer adjuvant that has been used in human clinical trials. PCPP promotes sustained antigen release while retaining antigenic integrity (25, 26). Another promising adjuvant for human use is
the nonionic block copolymer mixture of polyoxyethylene
(POE) and polyoxypropylene (POP) (Vaxcel, Inc., Norcross,
Ga.). By varying both the molecular weight and the proportions of hydrophilic and hydrophobic components of the POP
and POE molecules, the formulations can be designed to
achieve differential levels and specificities of adjuvant activity
(21, 44). One of these copolymer mixtures, termed CRL-1005,
has been used to augment the immune response of mice and
rhesus monkeys to a commercially available human influenza
vaccine (42, 43).
To date none of these adjuvants have been tested for their
efficacy in enhancing immune responses directed against small
synthetic peptides. In the present study, TcpA peptides 4 and
6 were formulated with either PCPP or CRL-1005 and used to
immunize adult CD-1 mice. The immune responses to peptides
alone and to the peptide-adjuvant mixture were assessed. The
efficacy of each combination was then determined by challenging infant mice born to vaccinated and nonvaccinated adults.
MATERIALS AND METHODS
Peptide antigens and challenge strain. Peptides corresponding to portions of
TcpA from classical biotype strain O395 were synthesized on an Applied Biosystems model 430A synthesizer using the N-hydroxybenzotriazole esters of
tert-butoxycarbonyl amino acids in an N-methylpyrrolidone solvent coupling system as described by the manufacturer. Peptides 4 and 6 correspond to amino acid
residues 145 to 168 and 174 to 199, respectively, of TcpA pilin (33). PCPP
adjuvant was kindly provided by Avant Immunotherapeutics, Inc. The POE and
POP copolymers (CRL-1005) were kindly provided by Vaxcel, Inc. V. cholerae
O395 (classical, Ogawa) was used for challenge studies after growth in LuriaBertani broth with a starting pH of 6.5 at 30°C for 18 h with aeration.
Experimental vaccination protocol. Female CD-1 mice, 6 to 8 weeks of age,
were immunized in groups of five for each experiment. For all experimental and
control formulations, mice were immunized three times subcutaneously at
4-week intervals. Experimental groups received formulations containing 100 g
of TcpA peptide/dose emulsified in adjuvant. The negative-control groups received phosphate-buffered saline (PBS) or adjuvant alone. For PCPP formulations, aqueous suspensions of TcpA peptides were freshly mixed with 100 g of
adjuvant/dose. The vaccine formulations containing TcpA peptide and the Vaxcel copolymer adjuvant were made by emulsifying 1 volume of aqueous antigen
with 1 volume of oil phase copolymer adjuvant. Four weeks after each immunization, sera were collected for antibody analysis. Four to 6 weeks after the third
immunization, female CD-1 mice were boosted intraperitoneally and mated with
male CD-1 mice. Newborn suckling pups (4 to 5 days old) from the immunized
or control mothers were used for challenge studies, with each challenge group
containing 8 to 12 neonatal mice.
Measurement and characterization of immune responses. Murine antibody
responses were measured by enzyme-linked immunosorbent assay (ELISA).

INFECT. IMMUN.
TcpA peptide antigens were diluted in PBS to a concentration of 5 g/ml and
passively adsorbed to the wells of Immulon-2 assay plates (Dynex Technologies,
Inc., Chantilly, Va.) by incubation of 100 l/well for 18 h at 4°C. Sera from
individual mice were diluted in PBS containing 4% (wt/vol) bovine serum albumin using a log10 titration scheme. For immunoglobulin G (IgG) subclass analysis, sera were serially diluted fivefold starting with a 1:10 dilution. Antibody
binding to the test antigen was detected using horseradish peroxidase (HRP)conjugated goat anti-mouse Igs (IgG and IgA; Sigma, St. Louis, Mo.) and
HRP-conjugated goat anti-IgG subclasses (IgG1, IgG2a, IgG2b, and IgG3),
obtained from Southern Biotechnology Associates, Inc. (Birmingham, Ala.).
HRP activity was measured using the colorimetric substrate 3⬘,3⬘,5⬘,5⬘-tetramethylbenzidine (Sigma), and the absorbance was read at 450 nm by a 96-well
microplate reader. Serum samples from individual mice were tested in triplicate
to determine the means and standard deviations (SD). Endpoint titers were
defined as the highest dilution of serum that yielded an absorbance value of at
least twice that of the background. The levels of mucosal secretory IgA were
approximated by measuring intestinal samples using the method described by
Dickinson and Clements (10). The small intestine from duodenum to ileal-cecal
junction was excised and homogenized with PBS. Samples were centrifuged, and
the supernatants were used in ELISA.
Determination of immunization efficacy using the infant mouse model. Neonatal mice (4 to 5 days old) were removed from mothers and orally challenged
with 1 LD50 (5 ⫻ 105 CFU) or 10 LD50 (5 ⫻ 106 CFU) of virulent V. cholerae
O395 (41). Animals were monitored for 48 h. After 48 h, any surviving animals
were euthanized and sera were collected for antibody analysis.
Statistical analyses. Antibody titers were scored as endpoint titers for a particular serum sample for individual mice in all groups. The log10 titers were used
to generate means and SD that were analyzed by analysis of variance (ANOVA)
and Tukey’s posttest analysis using Prizm software (Graph Pad Software, San
Diego, Calif.). The survival curves were also generated using Prizm software.
Survival fractions were calculated using the Kaplan-Meier method. To compare
survival curves, the log rank test was used to determine if there was a linear trend
for the survival curves. Statistical comparisons were based on the null hypothesis
that the treatment did not change the slope of the curves. P values of ⬎0.05 are
not considered significant.

RESULTS
Enhanced immunogenicity of TcpA synthetic peptides in the
presence of copolymer adjuvants. Previously, rabbit polyclonal
antibodies were raised against individual TCP peptides TcpA4
and TcpA6 coupled to keyhole limpet hemocyanin and emulsified in Freund’s complete adjuvant (31, 32). Anti-TcpA4 sera
(titer of 1:3,200) were shown to be very effective at providing
passive immunity against cholera infection in the infant mouse
cholera model, while the sera specific for TcpA6 (1:3,200) were
somewhat less effective.
To determine if it was possible to raise protective antibody
responses against the TcpA4 and TcpA6 peptides delivered
with adjuvants approved for human vaccine trials, the peptides
without carrier protein (keyhole limpet hemocyanin) were
combined with the PCPP or CRL-1005 polymer adjuvant. The
formulations were used to immunize adult female CD-1 mice
subcutaneously three times at 4-week intervals. Serum antiTcpA4 or anti-TcpA6 titers resulting from each immunization
were measured by ELISA using the corresponding TcpA peptides as the test antigens (Fig. 1).
The initial titers of the first immunization were low regardless of the group assessed. With respect to TcpA4, only the
TcpA4-plus-PCPP response in the primary sera was significantly higher than that in sera from mice that received peptide
alone. In contrast, both adjuvants significantly enhanced the
anti-TcpA6 responses in the primary sera. The titers measured
after inoculation of PBS or adjuvant alone were similar. Adjuvant alone did not induce anti-TcpA4 or anti-TcpA6 titers
(data not shown).
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FIG. 1. Measurement of mouse serum antibodies to TcpA4 and TcpA6 peptides by ELISA. Female CD-1 mice were immunized with TcpA
peptides alone and TcpA peptides formulated with PCPP or CRL-1005 copolymer adjuvants. All mice were immunized three times at 4-week
intervals. Serum samples were taken 4 weeks after each immunization. The data shown represent the log10 means of the endpoint titers. The data
were evaluated by ANOVA and Tukey multiple means comparison test. Those means which are significantly different within a group comparison
(e.g., for the tertiary-serum comparison, TcpA4 alone [ⴱ] versus TcpA4 plus PCPP [ⴱⴱ] or TcpA4 plus CRL-1005 [ⴱⴱⴱ]) have different numbers
of asterisks above the bar. Immunization of mice with PBS or either adjuvant alone did not induce anti-TcpA peptide titers (data not shown).

Mice that had received either peptide formulated with either
adjuvant had significantly higher anti-TcpA peptide response
to the corresponding peptide after the second immunization
than mice that received peptide antigens alone. There were
63-fold (anti-TcpA4) and 14.4-fold (anti-TcpA6) increases in
the titer between the primary and secondary immunizations
with TcpA peptide alone. This is in contrast to approximately
a 3-log-unit increase in titer for anti-TcpA4 sera if either adjuvant was included. Similarly, the use of adjuvants for TcpA6
increased the titers for the secondary sera over those for the
primary sera (TcpA6 plus PCPP, 66-fold; TcpA6 plus CRL1005, 60.2-fold). The immunoenhancing effect of adjuvant is
higher (four- to eightfold) for immunization with TcpA4 than
for immunization with TcpA6.
After three immunizations with TcpA4 or TcpA6 alone,
anti-TcpA titers were always lower than the titers for mice that
received TcpA peptides and adjuvant. Immunization with peptides alone caused a greater increase in the tertiary-serum
titers than immunization with peptides and either adjuvant.
The increases in anti-TcpA peptide titers for mice immunized
with peptides only were 32.7-fold and 104.5-fold for TcpA4 and
TcpA6, respectively. This is in contrast to only a 4.3-fold average increase in titers for the secondary and tertiary sera of
mice immunized with either peptide and either adjuvant, suggesting that the titers were maximized earlier if adjuvant was
used. In all comparisons, for peptides alone versus peptides
plus either adjuvant, the adjuvant significantly increased the
anti-TcpA peptide response except for the primary response to
TcpA4 plus CRL-1005.
Characterization of the Ig profile induced by vaccination
with the peptides alone and in combination with the polymer
adjuvants. To characterize the nature of the immune responses induced by the peptide-adjuvant formulations, the anti-TcpA peptide titers of IgG subclasses and of IgA (serum and

secretory IgA [sIgA]) were determined from mice after the
third immunization with the TcpA4 and TcpA6 peptides alone
or peptides in combination with the PCPP or CRL-1005 adjuvant (Table 1). This analysis revealed that the vaccine formulations induced a broad spectrum of IgG subclasses (IgG1,
IgG2a, IgG2b, and IgG3), with IgG1 and IgG2a being predominant.
Surprisingly, the degree of titer enhancement of various
subclass responses was dependent on the specific peptide-adjuvant combination. For TcpA4, the PCPP adjuvant formulation increased all IgG subclasses as well as IgA, serum or
secretory, to a greater extent (average of 11.3-fold versus an
average of 6.5-fold) than the CRL-1005 adjuvant. For TcpA6,
CRL-1005 increased the response on average 16.6-fold while
PCPP increased the response on average 9.6-fold. The most
remarkable effects of the adjuvants were consistently seen in
the IgG1 (average 20-fold increase) and IgA (average 12.4-fold
increase) responses. The other IgG subclasses increased on
average 7-fold (range, 2.3-fold to 33.3-fold).
Statistical analysis of individual subclass and isotype titers
for anti-TcpA4 or anti-TcpA6 revealed a pattern similar to that
presented in Fig. 1. The major difference in the data presented
in Table 1 versus that in Fig. 1 is that the analysis of the IgG2b
and IgG3 subclass responses revealed that in general they did
not differ from that induced by peptides alone. This was true
except in two cases: (i) TcpA4 plus PCPP, for which the response was different from that for peptides alone, and (ii)
TcpA6 plus CRL-1005, for which the response was different
from that for TcpA6 alone. As a whole the IgG1, IgG2a, and
IgA responses with peptides plus either adjuvant were significantly higher than those with peptides alone.
Induction of protective host immunity by TcpA peptide vaccine formulations. Since the acquisition of passive immunity in
young children from mother’s milk is one of the goals of chol-
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TABLE 1. Antibody isotypes and subclasses induced by TcpA peptides and vaccine formulations containing polymer adjuvantsa
Antigen

Mean antibody titers for adult female CD-1 micec ⫾ SD for:
IgG1

IgG2a

IgG2b

TcpA4
TcpA4 ⫹ PCPP
TcpA4 ⫹ CRL-1005

200 ⫾ 87ⴱ
4,167 ⫾ 160ⴱⴱ (20.8)
2,333 ⫾ 16ⴱⴱ (11.7)

337 ⫾ 42ⴱ
1,167 ⫾ 44ⴱⴱ (3.5)
917 ⫾ 90ⴱ (2.7)

10 ⫾ 0.01ⴱ
83 ⫾ 29ⴱⴱ (8.3)
37 ⫾ 12ⴱ (3.7)

TcpA6
TcpA6 ⫹ PCPP
TcpA6 ⫹ CRL-1005

112 ⫾ 10ⴱ
2,833 ⫾ 108ⴱⴱ (25.3)
2,500 ⫾ 175ⴱⴱ (22.3)

50 ⫾ 0.01ⴱ
283 ⫾ 18ⴱⴱ (5.7)
1,667 ⫾ 28† (33.3)

10 ⫾ 0.01ⴱ
23 ⫾ 6ⴱ (2.3)
50 ⫾ 0.01ⴱⴱ (5.0)

Serum IgA

sIgAb

50 ⫾ 1.2ⴱ
417 ⫾ 74ⴱ (8.3)
200 ⫾ 64ⴱ (4.0)

10 ⫾ 0.01ⴱ
100 ⫾ 0.1ⴱ (10.0)
83 ⫾ 9.7ⴱⴱ (8.3)

50 ⫾ 17ⴱ
542 ⫾ 72ⴱⴱ (16.8)
417 ⫾ 24ⴱⴱ (8.3)

37 ⫾ 9.6ⴱ
150 ⫾ 87ⴱ (4.1)
100 ⫾ 0.01ⴱ (2.7)

10 ⫾ 0.01ⴱ
108 ⫾ 25ⴱⴱ (10.8)
200 ⫾ 48ⴱⴱ (20.0)

ND
ND
ND

IgG3

a
Antibody responses of adult female CD-1 mice were measured by ELISA. All mice were immunized three times at 4-week intervals. Serum samples were taken
4 weeks after the last immunization. Mean titers were determined from log10 endpoint titers for each experimental group. ND, not determined.
b
sIgA, IgA from intestinal tissue.
c
The symbols after the values for each group indicate Tukey’s multiple means comparisons of the ANOVA results for that group. The comparisons are peptide to
peptide plus PCPP, peptide to peptide plus CRL-1005, and peptide plus PCPP to peptide plus CRL-1005. Symbols that are the same indicate the mean titer comparisons
within that group have a P value of ⬎0.05; those that are different have a P value of ⬍0.05 and thus the titers are significantly different. Numbers in parentheses are
the fold increases of the anti-TcpA peptide titers of mice immunized with peptides and adjuvant compared to those for mice immunized with TcpA4 or TcpA6 peptide
alone.

era vaccine development, we used a modification of the infant
mouse protection assay based on the types of methods used in
rotavirus vaccine development, whereby mothers are immunized and protective antibodies are acquired by placental
transfer or in milk (5, 7, 23, 24, 29). The use of this method not
only assesses the ability of the immunization regimen to select
a VDJ, VJ solution for the specific antibodies but also assesses
the efficacy of inducing a functional antibody that is delivered
via natural means, which is not the case in the typical infant
mouse cholera protection assay. In this study, after the third
immunization, females were mated and pups were born on
average 35 days postimmunization. Newborn CD-1 suckling
pups were challenged with either 1 LD50 (5 ⫻ 105 CFU) or 10

LD50 (5 ⫻ 106 CFU) of virulent V. cholerae O395, and the
survival rate was monitored for 48 h (Fig. 2). Statistical comparisons of the survival curves for selected treatment groups
are shown in Table 2. For vaccine formulations that included
TcpA4, the results with the polymer adjuvants were nearly
identical. All the neonatal mice from mothers immunized with
TcpA4 plus polymer adjuvant survived the 1-LD50 challenge
(Fig. 2A). This difference was statistically significant (P ⫽
0.0017 for PBS versus TcpA4 plus PCPP; P ⫽ 0.0017 for PBS
versus TcpA4 plus CRL-1005) in comparison with that for the
neonatal mice born to nonimmunized CD-1 mothers given
PBS (Table 2). The difference in protection afforded by the
adjuvants was not significant. Neonatal mice from mothers

FIG. 2. Protection from O395 challenge of neonatal CD-1 mice born to mothers immunized with TcpA4, TcpA4 plus PCPP, TcpA4 plus
CRL-1005, TcpA6, TcpA6 plus PCPP, or TcpA6 plus CRL-1005. Five-day-old neonatal mice born to mothers immunized with TcpA4, TcpA4 plus
PCPP, or TcpA4 plus CRL-1005 adjuvant (10 to 14 neonatal mice from each experimental group for TcpA4) were challenged with 1 LD50 (A) or
10 LD50 (B) of virulent V. cholerae O395. For TcpA6-immunized groups, eight neonatal mice were challenged with 1 LD50 (C) or 10 LD50 (D)
of virulent V. cholerae O395. The survival rates were monitored every 2 h for 48 h. The data shown represent the combined results of two
independent experiments.
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TABLE 2. Correlation of anti-TcpA-peptide titers with protection for this study and others
Challenge method/dosea

In vitro studies
In vitro mix/500 LD50
In vitro mix/500 LD50
In vitro mix/500 LD50

Anti-TCP titer
(% protection)

NDb
1:79,400 (100)
1:32,000 (87.5)

In vitro study
In vivo mix/1 LD50
In vivo mix/10 LD50
In vivo mix/1 LD50
In vivo mix/10 LD50
In vivo mix/1 LD50
In vivo mix/10 LD50
In vivo mix/1 LD50
In vivo mix/10 LD50
In vivo mix/1 LD50
In vivo mix/10 LD50
In vivo mix/1 LD50
In vivo mix/10 LD50

Anti-TcpA4 titer
(% protection)

Anti-TcpA6 titer
(% protection)

Reference
or study

1:3,200 (89)
ND
ND

1:3,200 (70)
ND
ND

32
29
29

1:200 (60)
1:200 (0)
ND
ND
1:2,333 (100)
1:2,333 (50)
1:4,167 (100)
1:4,167 (50)
ND
ND
ND
ND

ND
ND
1:112 (50)
1:112 (0)
ND
ND
ND
ND
1:2,500 (75)
1:2,500 (33)
1:2,833 (100)
1:2,833 (50)

This
This
This
This
This
This
This
This
This
This
This
This

study
study
study
study
study
study
study
study
study
study
study
study

a
In vitro mix, infant mouse assay in which viable pathogenic V. cholerae is mixed 1:1 with antisera (usually undiluted) and then the mixture is introduced
intragastrically to neonatal mice through gavage; in vivo mix, method utilized in the present study, in which 6- to 8-week-old female mice undergo an immunization
regimen and the efficacy is tested by challenging their infants with V. cholerae at 1 LD50 or 10 LD50.
b
ND, not determined.

immunized with TcpA4 peptide alone were partially protected
(60%) from 1 LD50, and the time until death was increased,
but the protection was not significantly different (Fig. 2A and
Table 2). The greater protection (1 LD50) for neonatal mice
born to mothers immunized with TcpA4 plus adjuvant than for
those immunized with TcpA4 alone was statistically significant
(P ⫽ 0.0297 for TcpA4 versus TcpA4 plus PCPP; P ⫽ 0.0297
for TcpA4 versus TcpA4 plus CRL-1005).
When neonatal mice were challenged with 10 LD50 of V.
cholerae O395, 50% of neonatal mice from mothers immunized
with TcpA4 plus adjuvant survived, compared to no surviving
pups from PBS-treated mothers (P ⬍ 0.0001 for PBS versus
TcpA4 plus PCPP; P ⬍ 0.0001 for PBS versus TcpA4 plus
CRL-1005) (Fig. 2B). All neonatal mice from mothers immunized with TcpA4 peptide only succumbed after 40 h, although
the time until death was increased in comparison with that for
neonatal mice born to PBS-treated mothers (P ⬍ 0.0001 for
PBS versus TcpA4). The infants that survived (immunized with
TcpA4 plus adjuvant) had specific anti-TcpA4 IgG antibody
titers ranging from 1:1,000 to 1:10,000 and detectable serum
IgA titers ranging from 1:10 to 1:50 (data not shown). The
survival of mice given TcpA4 alone was significantly different
from that of mice given the peptide plus adjuvant if the adjuvant was PCPP (P ⫽ 0.0149) but not if it was CRL-1005 (P ⫽
0.0618). The levels of protection afforded by either adjuvant
with TcpA4 were not significantly different (P ⫽ 0.6640). For
TcpA6 formulations, there was a greater difference in the efficacy of the two polymer adjuvants than was seen for TcpA4
formulations. Infant mice born to mothers immunized with
TcpA6 plus PCPP adjuvant were 100% protected (P ⫽ 0.0045
for PBS versus TcpA6 plus PCPP) against a 1-LD50 challenge
(Fig. 2C) and 50% protected (P ⬍ 0.0001 for PBS versus
TcpA6 plus PCPP) against a 10-LD50 challenge (Fig. 2D).
Infant mice born to mothers immunized with TcpA6 and copolymer CRL-1005 showed a lower (75%), but still statistically
significant (P ⫽ 0.0394 for PBS versus TcpA6 plus CRL-1005),

protection rate against a 1-LD50 challenge (Fig. 2C). The protection afforded infant mice vaccinated with the TcpA6-plusCRL-1005 formulation against the 10-LD50 challenge was also
statistically significant (P ⬍ 0.0001 for PBS versus TcpA6 plus
CRL-1005), but only 33% of the mice survived the challenge
(Fig. 2D). The use of TcpA6 peptide alone to vaccinate produced some protection at 1 LD50, but the protection was not
significantly different from that for mothers that received PBS
(P ⫽ 0.2562 for PBS versus TcpA6). However, the protection
afforded by TcpA6 was significant (P ⫽ 0.002 for PBS versus
TcpA6) with a 10-LD50 challenge dose. If the protection afforded by the TcpA6 peptide alone and the protection afforded
by the peptide emulsified in either PCPP or CRL-1005 are
compared, it is obvious that the inclusion of the adjuvant is
effective against 1 LD50 (P ⫽ 0.0250 for TcpA6 versus TcpA6
plus PCPP, and P ⫽ 0.0250 for TcpA6 versus TcpA6 plus
CRL-1005) but not against 10 LD50 (P ⫽ 0.5260 for TcpA6
versus TcpA6 plus PCPP, and P ⫽ 0.2223 for TcpA6 versus
TcpA6 plus CRL-1005). At either challenge level, the difference in protection by either adjuvant was not significant (for 1
LD50 P ⫽ 0.7720, and for 10 LD50 P ⫽ 0.4998).
Interestingly, and similar to the results noted for TcpA4 plus
adjuvant, sera of pups that survived infection from each group
had specific IgG antibody titers in the range of 1:1,000 to
1:10,000. They also had detectable serum IgA antibody titers of
1:10 to 1:50.
Titer, antibody source, and LD50 influence survival. We
correlated the serologic titer of the IgG1 responses to peptides
alone or preparations of peptides with the two adjuvants to the
percent protection provided in the modified infant mouse challenge assay (Fig. 3). We chose to focus on IgG1 as it is representative of the isotypes (IgG1 and IgA) that completely correlate with protection. We developed a model that relates the
mean log10 titer of the mice for a particular treatment group/
LD50 of bacteria given plotted against the percent protection.
Retrospective data (Table 3) for percent protection following
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TABLE 3. Tabulation of log rank comparisons indicating the
statistical significance of various treatment regimens on protection
in the infant mouse challenge assaya
Peptide, dose, and comparison

FIG. 3. Correlation of the percent protection in the neonatal
mouse assay with anti-TcpA titer/LD50. Data from this study and from
others presented in Table 2 were used to generate curves that show the
relationship between anti-TcpA titer and LD50 challenge dose and the
percent protection provided by an antibody mixed with bacteria in vitro
or obtained passively in vivo. The in vitro studies used 500 LD50, while
the in vivo curve based on data from this study combined data for pups
challenged with either 1 LD50 or 10 LD50. The curves were generated
using the Prizm program, whereby the percent protection was plotted
against log10 transformed titer/LD50. The equations for each curve are
representative of the standard equation for a line, y ⫽ (slope ⫾ SDx ⫹
y intercept ⫾ SD).

in vitro mixing of antibody and bacteria were also analyzed and
compared to the trend of the line for antibody mixed with
bacteria in vivo. There is a direct correlation of anti-TcpA
IgG1 titers and protection. The slopes are significantly different from each other (in vivo, 31.47; in vitro, 12.92) and indicate
that, if bacteria are mixed with antibodies in vitro, the protection does not fall off as quickly as it does if they are mixed in
vivo. For example, if the ratio of the log10 titer is 2 to 1, for the
in vivo mixture the protection decreases from 50.4 to 19.0%.
The decrease for an in vitro mixture is a change of only about
13% (94.3 to 81.4%).
DISCUSSION
In this report, we show that TcpA peptide antigens formulated with newly developed adjuvants intended for use in humans can be used to immunize adult female CD-1 mice, which
can then provide passive immunity to their neonatal offspring.
Vaccine formulations containing TcpA4 or TcpA6 peptides
emulsified in PCPP or CRL-1005 adjuvants augmented antibody responses beyond those achieved for either peptide
alone, which in turn corresponded to greater protection
against V. cholerae challenge. The amount of peptide used in
these studies, 100 g, is on the high end of the immunogenic
dose in mice. Smaller amounts of TcpA peptides (e.g., 25 g)
are immunogenic even if given in only two immunizations
(W. F. Wade, personal observation). However, the dose and
immunization schedule and route of administration of TcpA
peptides in humans remain to be determined, and the amount
of antigen will likely be different depending on the route and
method chosen to deliver the peptides.
The finding that the vaccine formulations containing the
TcpA4 peptide were more protective than those containing
TcpA6 is consistent with previous passive immunization stud-

P

Significance

TcpA4
1 LD50
PBS vs TcpA4
PBS vs TcpA4/PCPP
PBS vs TcpA4/CRL-1005
TcpA4 vs TcpA4/PCPP
TcpA4 vs TcpA4/CRL-1005
TcpA4/PCCP vs TcpA4/CRL-1005

0.0679
0.0017
0.0017
0.0297
0.0297
0.9999

No
Yes
Yes
Yes
Yes
No

10 LD50
PBS vs TcpA4
PBS vs TcpA4/PCPP
PBS vs TcpA4/CRL-1005
TcpA4 vs TcpA4/PCPP
TcpA4 vs TcpA4/CRL-1005
TcpA4/PCPP vs TcpA4/CRL-1005

⬍0.0001
⬍0.0001
⬍0.0001
0.0159
0.0618
0.6640

Yes
Yes
Yes
Yes
No
No

TcpA6
1 LD50
PBS vs TcpA6
PBS vs TcpA6/PCPP
PBS vs TcpA6/CRL-1005
TcpA6 vs TcpA6/PCPP
TcpA6 vs TcpA6/CRL-1005
TcpA6/PCCP vs TcpA6/CRL-1005

0.2560
0.0045
0.0394
0.0250
0.7772
0.1435

No
Yes
Yes
Yes
No
No

10 LD50
PBS vs TcpA6
PBS vs TcpA6/PCPP
PBS vs TcpA6/CRL-1005
TcpA6 vs TcpA6/PCPP
TcpA6 vs TcpA6/CRL-1005
TcpA6/PCpP vs TcpA6/CRL-1005

0.0020
⬍0.0001
⬍0.0001
0.5260
0.2223
0.4988

Yes
Yes
Yes
No
No
No

a
To compare survival curves, the Prizm software was used to perform the log
rank test. Statistical comparisons were based on the null hypothesis that the
treatment did not change the slope of the curves. Infant mice were challenged
with either 1 LD50 or 10 LD50 and monitored for 48 h to determine time of death
(Fig. 2). Individual comparisons were made as indicated; P values of ⬎0.05 are
not considered significant.

ies (34). Importantly, female mice immunized with TcpA peptides in adjuvant were able to transfer an antibody that was
protective to suckling pups challenged with virulent V. cholerae
O1. It is not known if the protective antibody in our present
report was present in milk, transferred through the placenta, or
both (1, 4). In humans, IgG has been shown to bind to placental Fc receptors, which facilitate its transport into the fetal
circulation (14). Alternatively, there is IgG among other isotypes present in human breast milk. The extension of the
adjuvants described in this study and TcpA peptides into humans could result in protective immunity due to IgG acquired
by several means. The identity of the protective isotype that is
most effective for protection against cholera is an open question. Historically, sIgA, which is usually present in mucosal
secretions, has been considered the likely protective isotype
against cholera. In support of the potential role of other isotypes, recent evidence indicates that IgG as well as IgM can
enter the gut and that the entry of IgG may be enhanced in the
local area where there is infection (3). The selective IgA deficiency is one of the most common immunodeficiencies, with
0.5% of the population having no or very low sIgA. There are
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no published reports of increased incidence of cholera or increased severity of disease in individuals of that phenotype.
These patients clearly respond to vaccination with cholera vaccines with increased IgG (22). More data need to be acquired
based on the responses of humans to determine the contribution of single or multiple isotypes to affording protection from
cholera.
The formulations of TcpA peptides with PCPP or copolymer
CRL-1005 adjuvants induced a broad spectrum of IgG subclasses. The highest titers were predominantly for the IgG1
and IgG2a subtypes, suggesting activation of both Th1 and Th2
type T helper cells. This is consistent with the PCPP-formulated influenza vaccine, which induced all IgG subclasses (14,
26). Copolymer CRL-1005 also activates both Th1 and Th2
type responses (43). While the TcpA-specific IgG induced by
the vaccine formulations could contribute to the protection
observed for the infant mice in the present study, a more
accepted mechanism of protection involves mucosal IgA. Studies have shown that both Th1 and Th2 type cytokines can
stimulate a mucosal immune response (8, 11, 19, 20).
Although the anti-TcpA peptide IgA titers induced by these
experimental vaccine formulations were not as high as the IgG
titers, they may contribute to the immune protection seen in
the infant mouse challenge. Clearly there were significant increases in sIgA that paralleled the IgG1 increase. Thus, this
adjuvant-peptide combination could be an important vaccine
component that would generate a protective antibody titer in
both the human intestine and breast milk. Since the protective
antigens of cholera have not been conclusively defined, it is
difficult to assess why people are protected after surviving
infection or being immunized with the current whole-cell vaccines. Clearly, antilipopolysaccharide (anti-LPS) titers increase
and the specific anti-LPS antibodies in the IgG and IgA compartments as well as in the IgM compartment can be measured.
Work in our laboratory suggests that certain somatic mutations
need to be acquired by the antibodies for anti-Ogawa immunity directed at the terminal LPS sugar (A. Chernyak et al.,
submitted for publication). However, since TcpA is not a
strong immunogen in natural infections, it is not known how
anti-TcpA antibodies mature upon repeated exposure to V.
cholerae. The elements of what make a protective anticholera
antiserum are usually associated with anti-LPS antibodies
rather than anti-TcpA antibodies. This, however, does not preclude TcpA from being used as an immunogen with the types
of adjuvants we described here. We expect that vaccination
with TcpA would result in TcpA serologic responses that
would also mature with the affinity and specificity that would
be protective for subsequent exposure to V. cholerae.
The means by which an anti-TcpA antibody is combined
with or is available along with the infectious inoculum is an
important issue to understand. The standard infant mouse
model mixes the antibody and bacteria in vitro, which is a very
efficient means of linking the antibody to target epitopes. In
the modification of the infant challenge assay that we report
here, the antibody has to transfer to the infant mouse naturally
and find the target epitope in the context of the gut milieu.
Thus, the amounts of antibodies (titer) needed for protection
for the two assays are likely to be different. A similar model to
evaluate the efficacy of vaccine preparation has been utilized in
studies of rotavirus. Rotavirus infection of infants causes dis-
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ease by replication of the virus in mature epithelial cells of the
small intestine. Like V. cholerae, rotavirus will not colonize the
intestines in adult animals (27). Most animal studies with respect to rotavirus vaccine development have been performed
by immunizing adult female mice and determining the efficacy
by challenge of infant mice (5, 7, 23, 24, 28). To our knowledge
this is the first study to show the efficacy of evaluating a maternally transferred mouse antibody for its role in protection
against cholera. This is particularly relevant as infants are often
cited as the population most at risk and are the targeted group
for improved vaccines. Our new method of challenge will allow
us to assess vaccine formulations in a setting that has direct
relevance to human health applications.
Our results show that TcpA peptides can be combined with
either PCPP or copolymer adjuvant CRL-1005 for use in inducing protective immunity to cholera infection. The V. cholerae TcpA antigen formulated with polymer adjuvants could
have utility for human use. A subunit or peptide vaccine would
be safer and less reactinogenic than a live cholera vaccine.
Subunit vaccines can also be rigorously standardized during
the manufacturing process, eliminating lot-to-lot variance that
is problematic with attenuated vaccines. TCP is an obvious
choice for this type of vaccine as it is a member of the type 4
pili, which contribute to the colonization capability of many
species of gram-negative bacteria, such as Neisseria gonorrhoeae, Pseudomonas aeruginosa, and pathogenic strains of
Escherichia coli (30).
Clearly, a data set that indicates that whole V. cholerae does
not have to be used to induce antibodies that can protect
against cholera is developing. The challenge is to find the right
formulation (antigens and adjuvants) and the most effective
method to deliver the vaccines that promote the concentration,
affinity, and fine specificity of the protective antibodies that
protect adults, children, and infants.
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